$3.48
+0.27 (+8.41%)
Open$3.31
Previous Close$3.21
Day High$3.60
Day Low$3.30
52W High$13.48
52W Low$1.98
Volume—
Avg Volume32.1K
Market Cap27.07M
P/E Ratio—
EPS$-5.24
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+1,205.2% upside
Current
$3.48
$3.48
Target
$45.42
$45.42
$30.66
$45.42 avg
$56.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.47M | 17.78M | 17.86M |
| Net Income | 823.9K | 633.2K | 616.7K |
| Profit Margin | 4.5% | 3.6% | 3.5% |
| EBITDA | 1.32M | 1.18M | 1.27M |
| Free Cash Flow | 745.4K | 469.0K | 453.6K |
| Rev Growth | +3.4% | -9.1% | -0.5% |
| Debt/Equity | 0.78 | 0.66 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |